Effects of FK228, a novel histone deacetylase inhibitor, on human lymphoma U-937 cells in vitro and in vivo (Q44138159)

30 November 2017

title

Effects of FK228, a novel histone deacetylase inhibitor, on human lymphoma U-937 cells in vitro and in vivo (English)

1 reference

30 November 2017

Yuka Sasakawa

1 reference

30 November 2017

Yoshinori Naoe

1 reference

30 November 2017

Takeshi Inoue

1 reference

30 November 2017

Tatsuya Sasakawa

1 reference

30 November 2017

Masahiko Matsuo

1 reference

30 November 2017

Toshitaka Manda

1 reference

30 November 2017

Seitaro Mutoh

1 reference

30 November 2017

language of work or name

English

0 references

publication date

1 October 2002

1 reference

30 November 2017

published in

Biochemical Pharmacology

1 reference

30 November 2017

1 reference

30 November 2017

1 reference

30 November 2017

page(s)

1079-1090

1 reference

FR901228, a novel antitumor bicyclic depsipeptide produced by Chromobacterium violaceum No. 968. I. Taxonomy, fermentation, isolation, physico-chemical and biological properties, and antitumor activity

30 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2802%2901261-3

FR901228, a novel antitumor bicyclic depsipeptide produced by Chromobacterium violaceum No. 968. III. Antitumor activities on experimental tumors in mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2802%2901261-3

FR901228, a potent antitumor antibiotic, is a novel histone deacetylase inhibitor.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2802%2901261-3

Histone acetylation in chromatin structure and transcription

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2802%2901261-3

The transcriptional coactivators p300 and CBP are histone acetyltransferases

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2802%2901261-3

The CBP co-activator is a histone acetyltransferase

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2802%2901261-3

A positive role for histone acetylation in transcription factor access to nucleosomal DNA

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2802%2901261-3

Repression and activation by multiprotein complexes that alter chromatin structure

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2802%2901261-3

Histone acetylation: influence on transcription, nucleosome mobility and positioning, and linker histone-dependent transcriptional repression

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2802%2901261-3

Histone deacetylase associated with mSin3A mediates repression by the acute promyelocytic leukemia-associated PLZF protein

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2802%2901261-3

Role of the histone deacetylase complex in acute promyelocytic leukaemia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2802%2901261-3

Fusion proteins of the retinoic acid receptor-alpha recruit histone deacetylase in promyelocytic leukaemia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2802%2901261-3

Distinct interactions of PML-RARalpha and PLZF-RARalpha with co-repressors determine differential responses to RA in APL.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2802%2901261-3

Histone deacetylase inhibitor but not arsenic trioxide differentiates acute promyelocytic leukaemia cells with t(11;17) in combination with all-trans retinoic acid

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2802%2901261-3

Butyric acid and its monosaccharide ester induce apoptosis in the HL-60 cell line

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2802%2901261-3

Control of HL-60 monocytic differentiation. Different pathways and uncoupled expression of differentiation markers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2802%2901261-3

p52(PAI-1) and actin expression in butyrate-induced flat revertants of v-ras-transformed rat kidney cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2802%2901261-3

Trichostatin A Induces Morphological Changes and Gelsolin Expression by Inhibiting Histone Deacetylase in Human Carcinoma Cell Lines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2802%2901261-3

A synthetic inhibitor of histone deacetylase, MS-27-275, with marked in vivo antitumor activity against human tumors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2802%2901261-3

Histone deacetylase inhibitor selectively induces p21WAF1 expression and gene-associated histone acetylation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2802%2901261-3

Inhibitor of histone deacetylation, depsipeptide (FR901228), in the treatment of peripheral and cutaneous T-cell lymphoma: a case report

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2802%2901261-3

Rapid colorimetric assay for cellular growth and survival: Application to proliferation and cytotoxicity assays

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2802%2901261-3

Human tumor models in the severe combined immune deficient ( scid ) mouse

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2802%2901261-3

Treatment of Philadelphia-chromosome-positive human leukemia in SCID mouse model with herbimycin A, bcr-abl tyrosine kinase activity inhibitor

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2802%2901261-3

Action of FR901228, a novel antitumor bicyclic depsipeptide produced by Chromobacterium violaceum no. 968, on Ha-ras transformed NIH3T3 cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2802%2901261-3

Effects of a novel antitumor depsipeptide, FR901228, on human breast cancer cells.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2802%2901261-3

The role of vitamin D derivatives and retinoids in the differentiation of human leukaemia cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2802%2901261-3

Effects of p21(Cip1/Waf1) at both the G1/S and the G2/M cell cycle transitions: pRb is a critical determinant in blocking DNA replication and in preventing endoreduplication

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2802%2901261-3

p53-independent expression of p21Cip1 in muscle and other terminally differentiating cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2802%2901261-3

Membrane proteins involved in phagocyte adherence to endothelium

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2802%2901261-3

The human macrophage cell line U937 as an in vitro model for selective evaluation of mycobacterial antigen-specific cytotoxic T-cell function

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2802%2901261-3

Histone Deacetylase Inhibitor Activates the WAF1/Cip1 Gene Promoter through the Sp1 Sites

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2802%2901261-3

Butyrate Activates the WAF1/Cip1 Gene Promoter through Sp1 Sites in a p53-negative Human Colon Cancer Cell Line

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2802%2901261-3

Activation of the p21WAF1/CIP1 promoter independent of p53 by the histone deacetylase inhibitor suberoylanilide hydroxamic acid (SAHA) through the Sp1 sites

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2802%2901261-3

Transcription factor ZBP-89 cooperates with histone acetyltransferase p300 during butyrate activation of p21waf1 transcription in human cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2802%2901261-3

Histone deacetylase 1 can repress transcription by binding to Sp1.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2802%2901261-3

p300 collaborates with Sp1 and Sp3 in p21(waf1/cip1) promoter activation induced by histone deacetylase inhibitor

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2802%2901261-3

Cloning of a GADD34-like gene that interacts with the zinc-finger transcription factor which binds to the p21(WAF) promoter

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2802%2901261-3

Histone deacetylase inhibition selectively alters the activity and expression of cell cycle proteins leading to specific chromatin acetylation and antiproliferative effects

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2802%2901261-3

Cloning and characterization of a histone deacetylase, HDAC9

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2802%2901261-3

Chemotherapy alone compared with chemotherapy plus radiotherapy for localized intermediate- and high-grade non-Hodgkin's lymphoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2802%2901261-3

Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2802%2901261-3

Interferon alfa combined with cytotoxic chemotherapy for patients with non-Hodgkin's lymphoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2802%2901261-3

Recombinant interferon alfa-2b combined with a regimen containing doxorubicin in patients with advanced follicular lymphoma. Groupe d'Etude des Lymphomes de l'Adulte

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2802%2901261-3

Interferon alpha consolidation after intensive chemotherapy does not prolong the progression-free survival of patients with low-grade non-Hodgkin's lymphoma: results of the Southwest Oncology Group randomized phase III study 8809

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2802%2901261-3

10.1016/S0006-2952(02)01261-3

7 January 2021

Identifiers

DOI

1 reference

30 November 2017

1 reference